Avatrombopag in Patients With End-stage Liver Disease and Thrombocytopenia

Exclusion Criteria

• •1. Subject has a history of arterial or venous thrombosis within the previous 6 months of baseline;
• •2. Known portal vein blood flow velocity rate \<10 cm/second or previous occurrence of a portal vein thrombosis within 6 months of Baseline;
• •3. Known any history of primary blood (e.g, immune thrombocytopenia, myelodysplastic syndrome, aplastic anemia);
• •4. Subject has a known medical history of genetic prothrombotic syndromes (e.g, Factor V Leiden prothrombin G20210A, antithrombin III (AT III) deficiency);
• •5. Subject has a recent history (within the previous 6 months) of significant cardiovascular diseases (e.g., exacerbation of congestive heart failure, arrhythmias known to increase the risk of thromboembolic events \[e.g. atrial fibrillation\], coronary or peripheral artery stent placement or angioplasty, and coronary or peripheral artery bypass grafting);
• •6. Female subjects who are lactating or pregnant at the Baseline Visit (as documented by a positive serum beta-human chorionic gonadotropin \[β-hCG\] test with a minimum sensitivity of 25 IU/L or equivalent units of β-hCG) or are planning to become pregnant during the study;
• •7. The subject has a hypersensitivity to Avatrombopag or any of its excipients;
• •8. Subjects with drug-induced thrombocytopenia;
• •9. Subjects whose Life expectation ≤6 months;
• •10. Subject with a current malignancy;
• •11. Subjects with HIV infection;
• •12. At screening, active infection was not effectively controlled by systemic antibiotic therapy;
• •13. The Investigator believe that any accompanying medical history may affect the safety of the subjects to complete the study;
• •14. The Investigator believe that there are any other factors that are not suitable for inclusion or affect participation or completion of the study;
• •15. Subject is enrolled in another clinical study with any investigational drug or device within previous 30 days of the Baseline Visit, but are allowed to participate in observational studies.